Editorial comment on 'Serum markers in breast cancer management'

European Journal of Cancer

Volumn 38, Issue 9, 2002, Pages 1165-1166

  Cheung, K L ^a  

^a NOTTINGHAM CITY HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CARCINOEMBRYONIC ANTIGEN; MUCIN; TRASTUZUMAB; TUMOR MARKER;

BONE METABOLISM; BONE METASTASIS; BONE SCINTISCANNING; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER GRADING; CANCER SCREENING; COST EFFECTIVENESS ANALYSIS; DISEASE COURSE; EDITORIAL; HISTOLOGY; HORMONAL THERAPY; HUMAN; LIVER SCINTISCANNING; METASTASIS; ONCOGENE C ERB; ONCOLOGY; POSTOPERATIVE COMPLICATION; PRIORITY JOURNAL; PROGNOSIS; RADIODIAGNOSIS; SIDE EFFECT; TUMOR VOLUME;

BREAST NEOPLASMS; CA-15-3 ANTIGEN; CARCINOEMBRYONIC ANTIGEN; FEMALE; HUMANS;

EID: 0036270417     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0959-8049(02)00069-2     Document Type: Editorial

References (10)

1. The prognostic value of the tumor marker CA 15-3 at initial diagnosis of patients with breast cancer
2. Prognostic role of serum CA15.3 in 362 node-negative breast cancers. An old player for a new game
3. CA 15-3 in the follow-up of localised breast cancer: A prospective study
4. Use of serial carcinoembryonic antigen and CA15.3 assays in detecting relapses in breast cancer patients
5. Breast cancer and clinical utility of CA15.3 and CEA
6. Increasing serum tumour markers as decision criteria for hormone-therapy of metastatic breast cancer
7. Prolonged survival by 'early' salvage treatment of breast cancer patients: A retrospective 6-year study
8. The objective measurement of remission progression in metastatic breast cancer by use of serum tumour markers
9. Continuous chemotherapy in responsive metastatic breast cancer: A role for tumour markers?
10. The guidelines for the management of metastatic bone disease in breast cancer in the United Kingdom